Highlights Altamira Therapeutics Nasdaq

Equities

CYTO

BMG0360L2099

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-15 pm EDT			5-day change	1st Jan Change
1.53 ^USD	+6.25%		+4.08%	-56.03%

May. 01	Altamira Therapeutics Ltd. Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation	CI
Apr. 24	Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Altamira Therapeutics Ltd. Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation	May. 01	CI
Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	Apr. 24	CI
Altamira Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10	CI
Sector Update: Health Care Stocks Decline Late Afternoon	Mar. 25	MT
Top Midday Gainers	Mar. 25	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	Mar. 25	MT
Altamira, Univercells Partner to Test mRNA Vaccine Delivery; Shares Surge	Mar. 25	MT
Altamira Therapeutics Ltd. Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines	Mar. 25	CI
Altamira Therapeutics? Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal	Feb. 07	CI
Altamira Files Second Provisional Patent Application in Cancer Treatment; Shares Rise	Jan. 24	MT
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment	Jan. 24	CI
Altamira Therapeutics Back in Compliance with Nasdaq Minimum Bid Price Rules	Dec. 29	MT
An unknown private equity investor acquired 51% stake in Altamira Medica AG from Altamira Therapeutics Ltd..	Nov. 20	CI
An unknown private equity investor entered into a binding agreement to acquire 51% stake in Altamira Medica AG from Altamira Therapeutics Ltd. for CHF 2.04 million.	Nov. 16	CI
Altamira Therapeutics Ltd. Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis	23-09-14	CI
Altamira Therapeutics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-12	CI
Altamira Therapeutics Collaborating With Pharma Nordic to Market, Distribute Bentrio Nasal Spray in Scandinavia	23-07-20	MT
Altamira Therapeutics, Heqet Therapeutics Enter Into Collaboration for OligoPhore Platform	23-07-05	MT
Altamira Therapeutics Receives Non-Compliance Notice From Nasdaq	23-06-30	MT
Altamira Therapeutics Ltd. Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome	23-06-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Altamira Therapeutics Nasdaq

Equities

CYTO

BMG0360L2099

Highlights

Filters